Stock listing
IPH Stock Price, News, Filings & Events — Innate Pharma Sa Class A
Selected listing: IPH · EURONEXT · EUR · FR
This page tracks Innate Pharma Sa Class A's IPH:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IPH:EURONEXT. IPH:EURONEXT is the stock-level entry point for investors researching Innate Pharma Sa Class A, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Innate Pharma Sa Class A, traded under the ticker IPH, is a public company based in France. The company has a market capitalization of approximately €170.86 million. Innate Pharma focuses on developing innovative immunotherapies for cancer treatment.
- Ticker
- IPH:EURONEXT
- Asset type
- Stock
- Market cap
- $206.7M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- EURONEXT
- Currency
- EUR
Innate Pharma Sa Class A IPH:EURONEXT stock context
This page tracks Innate Pharma Sa Class A's IPH:EURONEXT listing on EURONEXT in EUR for FR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following IPH:EURONEXT. IPH:EURONEXT is the stock-level entry point for investors researching Innate Pharma Sa Class A, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Innate Pharma Sa Class A, traded under the ticker IPH, is a public company based in France. The company has a market capitalization of approximately €170.86 million. Innate Pharma focuses on developing innovative immunotherapies for cancer treatment.
Latest news from Innate Pharma Sa Class A
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
September 10, 2026
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 2, 2026
Innate Pharma : Announces Pricing of €30 million Offering of Ordinary Shares
August 14, 2026
Innate Pharma Announces Proposed Offering of Ordinary Shares
August 13, 2026
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
August 10, 2026
Innate Pharma Sa Class A earnings calls
Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call
May 13, 2026 · Replay with transcript and chapters
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call
March 26, 2026 · Replay with transcript and chapters
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call
November 13, 2025 · Replay with transcript and chapters
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call
September 17, 2025 · Replay with transcript and chapters
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call
May 13, 2025 · Replay with transcript and chapters
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call
March 27, 2025 · Replay with transcript and chapters
Research Innate Pharma Sa Class A
Innate Pharma Sa Class A investor report
Review AI stock analysis and investor report context for IPH:EURONEXT.
Innate Pharma Sa Class A company profile
View the public company page for Innate Pharma Sa Class A on 6ix.
Innate Pharma Sa Class A news
Read company news and market updates connected to Innate Pharma Sa Class A.
Innate Pharma Sa Class A investor events
Find investor webinars, events, and replay context for Innate Pharma Sa Class A.
Alternate listings
IPHA:NASDAQ
US · USD
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IDD:GETTEX
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
4IPH:EUROTLX
IT · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IPHYF:OTC
US · USD
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
0EVI:LSIN
GB · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
A0LCUJ:LSX
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IPHP:AQUISEU
GB · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
A0LCUJ:LS
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IPHP:AQUISUK
GB · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IDD:SWB
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IDD:XETR
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.
IDD:TRADEGATE
DE · EUR
Alternate listing for Innate Pharma Sa Class A; the primary context on this page is IPH:EURONEXT.